glp-1 meds corona The role of receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism Researchers are launching a new

Over time, clinical trials run by Novo Nordisk and Eli Lilly showed that patients not only improved their blood sugar control but also experienced significant weight loss

Oct 23: Ulcerative colitis (UC) and Crohns disease (CD) patients who have previously used intravenous infliximab now have a subcutaneous option after the FDA approved Celltrions Zymfentra on Monday

Mesenchymal stem Cell-Derived extracellular vesicles: challenges in clinical applications [J]

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics report positive topline data from 8 mg dose of phase 2 obesity trial of GLP-1/GIP receptor dual agonist HRS9531